Literature DB >> 8199036

Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha.

C Messora1, L Bensi, A Vecchi, R Longo, F Giacobbi, P Temperani, M Bevini, G Emilia, S Sacchi.   

Abstract

Polycythaemia vera is a clonal disorder of the haemopoietic stem cell causing a pathologic expansion of the erythroid and sometimes the megakaryocytic and myeloid elements. In order to avoid the possible mutagenic effects of radioactive phosphorus, alkylating agents and hydroxyurea, since 1988 alpha-IFN has been used for the treatment of PV and has been shown to induce and maintain haematological remission. We describe a 24-year-old PV patient with chromosomal abnormalities who achieved not only a reduction of the proliferation of erythroid elements and reticulin content in the bone marrow, but also a complete cytogenetic remission after IFN treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199036     DOI: 10.1111/j.1365-2141.1994.tb04752.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors:  Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal:  Blood       Date:  2012-08-07       Impact factor: 22.113

2.  Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.

Authors:  Min Lu; Jiapeng Wang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

3.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

4.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

5.  Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Authors:  Min Lu; Wei Zhang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; Jiapeng Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

6.  A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera.

Authors:  S Sacchi; P Leoni; M Liberati; A Riccardi; A Tabilio; P Tartoni; C Messora; A Vecchi; L Bensi; S Rupoli
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

Review 7.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

Review 8.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.